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Abstract: Ozone (O3) is a natural, highly unstable atmospheric gas that rapidly decomposes to oxygen.
Although not being a radical molecule, O3 is a very strong oxidant and therefore it is potentially
toxic for living organisms. However, scientific evidence proved that the effects of O3 exposure are
dose-dependent: high dosages stimulate severe oxidative stress resulting in inflammatory response
and tissue injury, whereas low O3 concentrations induce a moderate oxidative eustress activating
antioxidant pathways. These properties make O3 a powerful medical tool, which can be used as either
a disinfectant or an adjuvant agent in the therapy of numerous diseases. In this paper, the cellular
mechanisms involved in the antioxidant response to O3 exposure will be reviewed with special
reference to the activation of nuclear factor erythroid 2-related factor 2 (Nrf2) and its role in the
efficacy of ozone therapy.
Keywords: ozone therapy; oxidative stress; proteostasis; mitochondria; inflammation; adipose
biology; cancer
1. Ozone in the Biomedical Field
Ozone (O3) is a natural gas forming from dioxygen (O2) by the action of ultraviolet light and
electrical discharges in the atmosphere; however, O3 is highly instable, rapidly breaking down to its
diatomic allotrope. For this reason, it occurs in very low amounts in the atmosphere compared to O2.
O3 is known as a strong oxidant being at the same time a dangerous respiratory hazard and pollutant
contributing to several diseases (recent review in [1–5]); it is also a powerful oxidizing agent with
manifold industrial applications (e.g., as disinfectant, deodorizer, cleaning and bleaching agent) [6–9]
and consumer implementations (e.g., as food additive, or air and water purifier) [10–13].
During the last decades, O3 has increasingly been applied as O2-O3 mixtures also in
complementary/adjuvant medicine. Actually, the medical use of O3 dates back to the 18th century [14],
when the Dutch physicist Martin van Marum discovered that an electric spark through the air gave rise
to a gas with a typical odour and strong oxidizing properties. However, the link between dioxygen
chemical modification and formation of the oxidant gas was only understood in 1840 by the German
chemist Christian Friedrich Schönbein who called this gas “ozone” (from the Greek word
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1. Ozone in the Biomedical Field 
Ozone (O3) is a natural gas forming from dioxygen (O2) by the action of ultraviolet light and 
electrical discharges in the atmosphere; however, O3 is highly instable, rapidly breaking down to its 
diatomic allotrope. For this reason, it occurs in very low amounts in the atmosphere compared to O2. 
O3 is known as a strong oxidant being at the same time a dangerous respiratory hazard and pollutant 
contributing to several diseases (recent review in [1–5]); it is also a powerful oxidizing agent with 
manifold industrial applications (e.g., as disinfectant, deodorizer, cleaning and bleaching agent) [6–
9] and consumer implementations (e.g., as food additive, or air and water purifier) [10–13].  
During the last decades, O3 has increasingly been applied as O2-O3 mixtures also in 
c mplementary/adjuvant medicine. Actually, the medical use of O3 dates back to the 18th century [14], 
when the Dutch physicist Martin van Marum discovered that an electric spark through the air gave 
rise to a gas with a typical odour and strong oxidizing properties. However, the link between 
dioxygen chemical modification and formation of the oxidant gas was only understood in 1840 by 
the German chemist Christian Friedrich Schönbein who called this gas “ozone” (from the Greek word 
ὄζειν, "to smell") and revealed its capability to interact with organic compounds. Subsequently, 
various generators of O3-O2 mixtures were built, and the first studies on the biological effects of O3 
were performed. Consequently, in the 19th century, O3 started to be used for therapeutic purposes, 
especially in treatment of allergy, and even Nikola Tesla patented an O3 generating system for 
medical use. During the last century, O3 was administered by different ways (gaseous O3 inhalation, 
injection or bags; auto-hemotherapy; ozonated water or oil) to treat a number of diseases (e.g., 
anaemia, diabetes, fever, gangrene, syphilis, tetanus, tuberculosis). Starting from late 1970s, O2-O3 
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“to smell”) and revealed its capability to interact with organic compounds. Subsequently, various
generators of O3-O2 mixtures were built, and the first studies on the biological effects of O3 were
performed. Consequently, in the 19th century, O3 started to be used for therapeutic purposes, esp cially
in treatment of allergy, and even Nikola Tesla patented an O3 generating system for medical use.
During the last century, O3 was administered by different ways (gaseous O3 inhalation, inject on or
bags; auto-hemotherapy; ozonated water or oil) to treat a number of diseases (e.g., anaemia, diabet s,
fever, gangrene, syphilis, tetanus, tuberculosis). Starting from late 1970s, O2-O3 therapy had a great
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development all over the world, thanks to the refinement of administration techniques and protocols,
and to the collaborative work of some European medical societies. This contributed significantly to
the set-up of regulatory requirements for O3 application, including the production of medical O3,
the use of appropriate disposable materials, and the definition of concentration, dosages, and treatment
frequency in relation to the disease [15]. In addition, based on clinical practice and according to the
principle of “hormesis” (i.e., “the beneficial effect of a low level exposure to an agent that is harmful at
high levels”) [16], a progressive lowering of O3 dosage has been adopted, relaying its beneficial effects
to the cascade of metabolic events triggered by the initial, mild oxidative stress [17].
In parallel to clinical advancement, an increasing number of scientific reports have been
published on the biomedical effects of O3 as adjuvant/alternative therapeutic approach for e.g.,
pain management [18–22], gastrointestinal diseases [23–27], lung diseases [28–31], diabetes [32–37],
ischemia [38–43], cancer [44–46], infective diseases [47–50], dentistry [51–56].
However, despite the wide scientific demonstration of the multiple therapeutic applications of
O2-O3 treatment, the biological mechanism(s) responsible for the positive effects of O3 administration
have been only partially elucidated.
2. Ozone-Induced Activation of the Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2)
Exposure to toxic levels of atmospheric O3 induces injury and inflammation through activation
of the redox sensitive nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), which
is one of the main players in transcribing pro-inflammatory cytokines and, in turn, in increasing the
expression of several proteins involved in the antioxidant response [47,57–65]. Among these proteins,
Nrf2 has been demonstrated to play a crucial role in the activation of cytoprotective antioxidant genes
against atmospheric pollutant-induced toxicity [66].
Similarly, exposure to low O3 concentrations for therapeutic purposes was found to act on Nrf2.
Ozonated serum was able to activate Nrf2 in a dose dependent manner and to subsequently induce
the expression of heme oxygenase 1 (HMOX1) and nicotinamide adenine dinucleotide phosphate
(NAD(P)H) quinone oxidoreductase 1 (NQO1) in endothelial cells [67]. Systemic O3 treatment in
healthy volunteers increased the levels of Nrf2 in peripheral blood mononuclear cells with consequent
enhanced activity of superoxide dismutase and catalase [68]. The application of ozonated saline in
an in vitro human keratinocyte model of wound healing proved the activation of Nrf2 pathways
resulting in the increased expression of the HMOX1 gene [69]. Systemic O3 administration in rats with
adenine-induced chronic kidney disease inhibited the NF-κB pathway and induced Nrf2 activation:
this resulted in the up-regulation of antioxidant enzymes and the down-regulation of inflammatory
cytokines in the kidney, with reduction of the renal insufficiency and tubulointerstitial injury [70].
Rectal insuﬄation of O3 to patients affected by multiple sclerosis increased Nrf2 phosphorylation
and casein kinase 2 (CK2) expression in mononuclear cells, thus improving the activity of antioxidant
enzymes and reducing the levels of pro-inflammatory cytokines [71]. The systemic administration of
O2-O3 was beneficial in the rat model of streptozotocin-induced pancreatic damage by increasing the
endogenous Nrf2 and glutathione-S-transferase (GST) in the pancreatic tissue [72]. O3 treatment in
rats induced oxidative preconditioning by activating Nrf2, thus protecting the lung and myocardium
from the ischemia-reperfusion injury, a major cause of cardiac and respiratory dysfunction during
cardiovascular surgery, heart transplantation and cardiopulmonary bypass procedures [73,74]. O2-O3
therapy proved to be beneficial also for the treatment of diabetic complications and spinal pain by
activating various antioxidant pathways involving hypoxia inducible factor-1α (HIF-1α), nuclear factor
of activated T-cells (NFAT), activated protein-1 (AP-1) pathways, and Nrf2 [75].
Based on these observations, it was hypothesized that the antioxidant and anti-inflammatory
effects of low O3 concentrations involve activation of Nrf2, which is thus considered as a key factor for
the efficacy of O2-O3 treatments [76–78].
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3. Biological Role of Nrf2 and Its Activation by Ozone Treatment
Nrf2 was first cloned in 1994 and identified as a member of the human cap‘n’collar basic-region
(CNC) leucine zipper transcription factor family [79], which also includes nuclear factor erythroid 2
(NF-E2), nuclear factor erythroid 2-related factor 1 (Nrf1), nuclear factor erythroid 2-related factor 3
(Nrf3), BTB domain and CNC homolog 1 (BACH1), and BTB domain and CNC homolog 2 (BACH2).
Nrf2 dimerizes with the small musculoaponeurotic fibrosarcoma (Maf) proteins to bind and mediate the
transcription at a consensus sequence containing an AP-1 core motif [80]; this latter was identified on
the promoter of the rat GST Ya subunit gene [81] and thereafter referred to as Antioxidant Responsive
Element (ARE) [82]. Under basal conditions, Nrf2 is expressed at very low level, and is mainly
sequestered in the cytoplasm by its specific inhibitor, Kelch-like ECH associated protein-1 (Keap-1) that
also promotes its rapid degradation [83]. The effectiveness of this mechanism allows a rapid turnover of
Nrf2, which displays a hemi-life of a few minutes. Under specific stimuli, Nrf2 dissociates from Keap1,
translocates into the nucleus and transactivates ARE-driven genes [84]. By combining sub-nuclear
tracking of Nrf2 localization and functional genetic engineering we have recently demonstrated that
mild ozonisation increases the nuclear translocation of Nrf2 at transcriptionally active chromatin sites,
inducing the Nrf2-mediated Keap1-dependent transcription of ARE-driven genes [85].
Twenty-five years of studies have contributed to identify more than two hundred ARE genes,
whose expression is regulated by the Nrf2 transcriptional activity. These genes encode for proteins
involved in a multitude of vital biological functions which include protein homeostasis, oxidative stress
response, detoxication, DNA repair, proliferation, autophagy, mitochondrial biogenesis and function,
inflammation, and the metabolism of lipids, carbohydrates and amino acids [86,87]. The impact
of Nrf2 on transcriptome is amplified by the fact that Nrf2 may directly regulate or bidirectionally
cross-talk with many other transcription factors such as Notch1 [88], the aryl hydrocarbon receptor
(AhR) [89], the CCAAT/enhancer-binding protein (C/EBPB) [90], the peroxisome proliferator-activated
receptor gamma (PPARγ) [91], the retinoid X receptor alpha (RXRA) and NF-κB. Finally, multiple lines
of evidence have shown that Nrf2 activation is part of the retrograde response aimed at restoring
mitochondrial function after stress insults, and that the impairment of Nrf2 functions is a hallmark of
many mitochondrial-related disorders [92–95].
Some of the cell functional pathways that are dependent on Nrf2 activation (Figure 1) are
summarized in the following paragraphs.
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3.1. Nrf2 and Oxidative Stress
Oxidative stress is due to the accumulation of reactive oxygen species (ROS) (O2−, H2O2 and
•OH), that are generated as by-products of either physiological or exogenous stress factors (such as,
e.g., the ionizing radiations). Although ROS have been recognized in the last years as functionally
significant signalling molecules for the modulation of the immune system, they have long been
seen as harmful factors with detrimental effect on cell homeostasis. For example, ROS are strong
inducers of DNA damage [96] that irreversibly compromises cell functions and might stimulate
neoplastic transformation [97]. Nrf2 prevents oxidative stress through the transcription of antioxidant
enzymes, such as the catalytic and modulatory subunits of glutamate cysteine ligase (GCL), glutathione
peroxidases (GPX2 and GPX4), glutathione reductase (GSR), peroxiredoxins (PRDX1 and PRDX6),
thioredoxin 1 and thioredoxin reductase 1 (TXN1 and TXNRD1), HMOX1, and biliverdin reductase
(BVR) [87,98–100]. Accordingly, we demonstrated that mild ozonisation induces modulation of genes
involved in the cell response to stress (HMOX1; excision repair cross-complementation group 4, ERCC4;
cyclin-dependent kinase inhibitor 1A, CDKN1A) and in the transcription machinery (CTD small
phosphatase 1, CTDSP1) [101].
3.2. Nrf2 and Proteostasis
Oxidative stress is one of the major drivers of protein misfolding as it induces protein oxidation.
Misfolded or unfolded proteins accumulate as insoluble inclusions and aggregates in the cytoplasm
and the cell nucleus, and are the hallmark of multiple aging-related neurodegenerative and metabolic
disorders [102]. Nrf2 promotes the clearance of oxidized or otherwise damaged proteins through the
two major pathways of protein degradation, i.e., the ubiquitin proteasome system and autophagy. Nrf2
directly targets the transcription of many proteasomal genes [103,104] and of the proteasome maturation
protein (POMP) [105]. Nrf2 also supports autophagy either directly (by regulating the transcription
of key autophagic genes, such as autophagy related ATG 5 and 7, unc-51-like autophagy activating
kinase (ULK) 1 and 2, and the autophagy transporter ubiquitin-binding protein p62, sequestosome-1
(SQSTM1) [106], or indirectly through the activation of mammalian target of rapamycin (mTOR),
a master regulator of protein synthesis and autophagy [107]. Consistently, O3 treatment proved to
promote wound healing by increasing the migration of fibroblasts via the phosphoinositide 3-kinase
(PI3K)/protein-kinase B (Akt)/mTOR signalling pathway [48], and to increase the level of autophagy
in a chondrocyte model of osteoarthritis through the activation of AMP-activated protein kinase
(AMPK)/mTOR [108].
3.3. Nrf2 and the Mitochondrial Function
The classic view of mitochondria as semi-independent organelles has recently been integrated
by the evidence that, in response to environmental changes, they may coordinate inter-organelle
signalling pathways (mitochondrial retrograde response) that ultimately instruct nuclear gene
expression [109–111]. Maintenance of an efficient mitochondrial function is crucial to preserve
cell homeostasis, as proven by the evidence that mitochondrial stimulation by mild-stress treatments
(mitohormesis) [112] underlies the beneficial effects of life-extending interventions such as dietary
restriction [113,114]. In contrast, mitochondrial dysfunction is ontologically linked (as either cause,
con-cause or consequence) to aging and aging-related diseases [115,116]. Nrf2 has been shown to
stimulate mitochondrial biogenesis through the activation of nuclear respiratory factor-1 (NRF-1)
in cardiomyocytes [117,118]. Cellular respiration and ATP synthesis are impaired in conditions of
Nrf2 deficiency and increased upon Keap1 loss of function [119,120]. Nrf2 is functionally linked
through a positive feedback loop to Sqstm1/p62, which localizes to the mitochondria and enhances the
mitochondrial transcription factor A (TFAM), a master regulator of mitochondrial biogenesis [121,122].
In addition, Nrf2 has been identified as a crucial mediator of the mitochondrial biogenesis induced by
acetyl-carnitine (ALCAR), nitric oxide (NO) and resveratrol [123,124]. Accordingly, mild ozonisation
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was found to affect mitochondria by increasing the length of the mitochondrial cristae and the content
of mitochondrial heat-shock protein 70 [125], while O3 treatment was proven to reduce mitochondrial
damage in a rat heart following ischemia-reperfusion [73] as well as in a rat brain and cochlea following
noise-induced hearing loss [126].
3.4. Nrf2 and Inflammation
Inflammatory pathways protect from exogenous harmful stimuli and, to some extent, from intrinsic
dysregulation of cell proliferation that may lead to neoplastic growth. However, inflammation may
also take place during aberrant self-reactivity in autoimmune diseases [127], while a low but chronic
level of inflammation in the absence of real exogenous or endogenous threats is a common hallmark of
aging (inflammaging) and aging-related diseases [128,129]. Nrf2 is able to modulate inflammation
through multiple mechanisms, such as the regulation of redox homeostasis and the suppression
of pro-inflammatory genes, either directly or through the interaction with NF-κB. Inflammation
increases local and systemic ROS level while ROS enhance inflammation [130]. The Nrf2-mediated
ROS-homeostatic control is able to break this vicious cycle. Nrf2 reduces inflammation by preventing
the recruitment of RNA polymerase II to start gene transcription of pro-inflammatory cytokines
IL-6 and IL1β [131]. In addition, Nrf2 tunes gene expression in inflammatory macrophages through
a bidirectional crosstalk with NF-κB transcription factor, and regulates the transcription of Nrf2
itself [132] that, in turn, inhibits the transcriptional activity of NF-κB [133]. NF-κB has long been
recognized as a point of convergence of inflammation and aging, and the array of NF-κB-regulated
genes largely overlaps with the targets of transcriptional/epigenetic regulators such as sirtuins that have
been demonstrated to promote lifespan extension [134–136]. This notion once again corroborates the
ontological link between inflammation and aging and allows speculation that O3-induced activation of
Nrf2 might be a potential tool to prevent aging and prolong lifespan.
3.5. Nrf2 and Adipose Biology
Oxidative stress is a crucial factor in adipocyte differentiation, and ROS are known to promote
adipogenesis via insulin-mediated signal transduction [137,138]. As an antioxidant regulator factor,
Nrf2 is involved in the adipogenic differentiation of mesenchymal stem cells [90,139,140], together with
HMOX-1 [141]. A recent study on 3T3-L1 cells suggested that Nrf2 affects adipocyte differentiation by
modulating the expression of the fibroblast growth factor 21 (FGF21) through the PPARγ, a master
transcription factor regulating inflammation as well as adipogenesis and insulin sensitization [142].
Consistently, treating the adipose tissue with low O3 concentrations proved to exert an adipogenic
effect on human adipose-derived adult stem cells [143] in the absence of damage in differentiated
adipocytes [144]; this allows foreseeing mild ozonisation as an adjuvant tool for tissue regeneration
and engineering.
3.6. Nrf2 and Cancer
Unlike the vast majority of diseases that have an often unique pathogenic cause, cancer can be
defined as multitude of possible pathologic states sharing the capability to subvert and redirect the
regeneration and differentiation potential of cells and tissues toward abnormal limitless proliferation
and growth. The Nrf2-mediated regulation of the biological processes described above has proven
to exert beneficial effects in preventing, ameliorating or curing a multitude of diseases, but might
turn detrimental in a cancer-related context. Nrf2 preserves cells from DNA damage, and therefore
might help preventing the primary trigger of neoplastic transformation. However, hyperactivation
of Nrf2 has been shown to support tumour progression by multiple ways [145,146]: for example,
it may help incipient tumour cells to overcome oxidative stress that represents a barrier against
neoplastic transformation and cancer initiation [147]. Also, Nrf2 hyperactivation supports aberrant cell
proliferation by both inducing the metabolic switch towards anabolic pathways [148] and modulating
mRNA translation [149]. Moreover, Nrf2 may promote tumour angiogenesis [150]. Finally, the
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potent cytoprotective effect of Nrf2 activation may confer drug resistance to cancer cells [151]. Thus,
the possible tumour-promoting effect of Nrf2 hyperactivation still remains a crucial issue, since
oncological patients are frequently administered O3 therapy due to its efficacy in reducing some
adverse side-effects of the anti-cancer treatments [46,152,153].
4. Conclusions
As a whole, the direct and indirect molecular targets of Nrf2 delineates a complex network of
biological processes that preserve cell homeostasis and promote cell reparative programs following
chemical, physical, or biological stress [154]. The complexity of the Nrf2 functional network does
not allow drawing an exhaustive molecular model that might explain the beneficial effects of O3 in
preventing or ameliorating diseases. Nrf2 activation exerts positive effects especially on diseases
that have oxidative stress and inflammation as primary etiopathological events [155,156]. Therefore,
it may be hypothesized that the therapeutic potential of Nrf2 activation as a consequence of mild
ozonisation relies on the capability of Nrf2 to maintain redox homeostasis: this would prevent DNA
damage, preserve proteostasis, and improve mitochondrial function while suppressing acute and
chronic inflammation.
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Nrf2 nuclear factor erythroid 2-related factor 2
NF-κB nuclear factor kappa-light-chain-enhancer of activated B cells
HMOX1 heme oxygenase 1
CK2 casein kinase 2
NAD(P)H nicotinamide adenine dinucleotide phosphate
NQO1 nicotinamide adenine dinucleotide phosphate quinone oxidoreductase 1
GST glutathione-S-transferase
HIF-1α hypoxia inducible factor-1α
NFAT nuclear factor of activated T-cells
AP-1 activated protein-1
CNC cap‘n’collar basic-region
NF-E2 nuclear factor erythroid 2
Nrf1 nuclear factor erythroid 2-related factor 1
Nrf3 nuclear factor erythroid 2-related factor 3
BACH1 BTB domain and CNC homolog 1
BACH2 BTB domain and CNC homolog 2
Maf musculoaponeurotic fibrosarcoma
ARE Antioxidant Responsive Element
Keap-1 Kelch-like ECH associated protein-1
AhR aryl hydrocarbon receptor
C/EBPB CCAAT/enhancer-binding protein
PPARγ peroxisome proliferator-activated receptor gamma
RXRA retinoid X receptor alpha
ROS reactive oxygen species
GCL glutamate cysteine ligase
GPX glutathione peroxidase
GSR glutathione reductase
PRDX peroxiredoxin
Int. J. Mol. Sci. 2019, 20, 4009 7 of 15
TXN1 thioredoxin 1
TXNRD1 thioredoxin reductase 1
BVR biliverdin reductase
ERCC4 excision repair cross-complementation group 4
CDKN1A cyclin-dependent kinase inhibitor 1A
CTDSP1 CTD small phosphatase 1
POMP proteasome maturation protein
ATG autophagy related
ULK unc-51-like autophagy activating kinase
SQSTM1 sequestosome-1
mTOR mammalian target of rapamycin
PI3K phosphoinositide 3-kinase
Akt protein-kinase B
AMPK adenosine monophosphate-activated protein kinase
NRF-1 nuclear respiratory factor-1
TFAM mitochondrial transcription factor A
ALCAR acetyl-carnitine
NO nitric oxide
FGF21 fibroblast growth factor 21
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